155 related articles for article (PubMed ID: 37307219)
41. Identification of hematein as a novel inhibitor of protein kinase CK2 from a natural product library.
Hung MS; Xu Z; Lin YC; Mao JH; Yang CT; Chang PJ; Jablons DM; You L
BMC Cancer; 2009 May; 9():135. PubMed ID: 19419583
[TBL] [Abstract][Full Text] [Related]
42. Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 ('casein kinase-2').
Sarno S; Reddy H; Meggio F; Ruzzene M; Davies SP; Donella-Deana A; Shugar D; Pinna LA
FEBS Lett; 2001 May; 496(1):44-8. PubMed ID: 11343704
[TBL] [Abstract][Full Text] [Related]
43. Structural basis of CX-4945 binding to human protein kinase CK2.
Ferguson AD; Sheth PR; Basso AD; Paliwal S; Gray K; Fischmann TO; Le HV
FEBS Lett; 2011 Jan; 585(1):104-10. PubMed ID: 21093442
[TBL] [Abstract][Full Text] [Related]
44. Casein Kinase II (CK2) as a Therapeutic Target for Hematological Malignancies.
Gowda C; Sachdev M; Muthusami S; Kapadia M; Petrovic-Dovat L; Hartman M; Ding Y; Song C; Payne JL; Tan BH; Dovat S
Curr Pharm Des; 2017; 23(1):95-107. PubMed ID: 27719640
[TBL] [Abstract][Full Text] [Related]
45. The replacement of ATP by the competitive inhibitor emodin induces conformational modifications in the catalytic site of protein kinase CK2.
Battistutta R; Sarno S; De Moliner E; Papinutto E; Zanotti G; Pinna LA
J Biol Chem; 2000 Sep; 275(38):29618-22. PubMed ID: 10882732
[TBL] [Abstract][Full Text] [Related]
46. Discovery of novel CK2 leads by cross-docking based virtual screening.
Sun H; Wu X; Xu X; Jiang Z; Liu Z; You Q
Med Chem; 2014; 10(6):628-39. PubMed ID: 24286395
[TBL] [Abstract][Full Text] [Related]
47. Conformational plasticity of the catalytic subunit of protein kinase CK2 and its consequences for regulation and drug design.
Niefind K; Issinger OG
Biochim Biophys Acta; 2010 Mar; 1804(3):484-92. PubMed ID: 19796713
[TBL] [Abstract][Full Text] [Related]
48. Comparing the efficacy and selectivity of Ck2 inhibitors. A phosphoproteomics approach.
Borgo C; Cesaro L; Hirota T; Kuwata K; D'Amore C; Ruppert T; Blatnik R; Salvi M; Pinna LA
Eur J Med Chem; 2021 Mar; 214():113217. PubMed ID: 33548633
[TBL] [Abstract][Full Text] [Related]
49. Exploring the Pivotal Role of the CK2 Hinge Region Sub-Pocket in Binding with Tricyclic Quinolone Analogues by Computational Analysis.
Zhou Y; Zhang N; Tang S; Qi X; Zhao L; Zhong R; Peng Y
Molecules; 2017 May; 22(5):. PubMed ID: 28534839
[TBL] [Abstract][Full Text] [Related]
50. Malaria protein kinase CK2 (PfCK2) shows novel mechanisms of regulation.
Graciotti M; Alam M; Solyakov L; Schmid R; Burley G; Bottrill AR; Doerig C; Cullis P; Tobin AB
PLoS One; 2014; 9(3):e85391. PubMed ID: 24658579
[TBL] [Abstract][Full Text] [Related]
51. Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer.
Pierre F; Chua PC; O'Brien SE; Siddiqui-Jain A; Bourbon P; Haddach M; Michaux J; Nagasawa J; Schwaebe MK; Stefan E; Vialettes A; Whitten JP; Chen TK; Darjania L; Stansfield R; Anderes K; Bliesath J; Drygin D; Ho C; Omori M; Proffitt C; Streiner N; Trent K; Rice WG; Ryckman DM
J Med Chem; 2011 Jan; 54(2):635-54. PubMed ID: 21174434
[TBL] [Abstract][Full Text] [Related]
52. Inclining the purine base binding plane in protein kinase CK2 by exchanging the flanking side-chains generates a preference for ATP as a cosubstrate.
Yde CW; Ermakova I; Issinger OG; Niefind K
J Mol Biol; 2005 Mar; 347(2):399-414. PubMed ID: 15740749
[TBL] [Abstract][Full Text] [Related]
53. The catalytic subunit of human protein kinase CK2 structurally deviates from its maize homologue in complex with the nucleotide competitive inhibitor emodin.
Raaf J; Klopffleisch K; Issinger OG; Niefind K
J Mol Biol; 2008 Mar; 377(1):1-8. PubMed ID: 18242640
[TBL] [Abstract][Full Text] [Related]
54. Protein kinase CK2 as a druggable target.
Sarno S; Pinna LA
Mol Biosyst; 2008 Sep; 4(9):889-94. PubMed ID: 18704226
[TBL] [Abstract][Full Text] [Related]
55. Synthesis, biological properties and structural study of new halogenated azolo[4,5-b]pyridines as inhibitors of CK2 kinase.
Chojnacki K; Lindenblatt D; Wińska P; Wielechowska M; Toelzer C; Niefind K; Bretner M
Bioorg Chem; 2021 Jan; 106():104502. PubMed ID: 33317841
[TBL] [Abstract][Full Text] [Related]
56. An overview about the impact of hinge region towards the anticancer binding affinity of the Ck2 ligands: a quantum chemical analysis.
Deepa P; Thirumeignanam D; Kolandaivel P
J Biomol Struct Dyn; 2019 Sep; 37(15):3859-3876. PubMed ID: 30301411
[TBL] [Abstract][Full Text] [Related]
57. Benzimidazole inhibitors of protein kinase CK2 potently inhibit the activity of atypical protein kinase Rio1.
Kubiński K; Masłyk M; Orzeszko A
Mol Cell Biochem; 2017 Feb; 426(1-2):195-203. PubMed ID: 27909846
[TBL] [Abstract][Full Text] [Related]
58. A promiscuous kinase inhibitor delineates the conspicuous structural features of protein kinase CK2a1.
Tsuyuguchi M; Nakaniwa T; Sawa M; Nakanishi I; Kinoshita T
Acta Crystallogr F Struct Biol Commun; 2019 Jul; 75(Pt 7):515-519. PubMed ID: 31282872
[TBL] [Abstract][Full Text] [Related]
59. A fragment-based approach leading to the discovery of a novel binding site and the selective CK2 inhibitor CAM4066.
De Fusco C; Brear P; Iegre J; Georgiou KH; Sore HF; Hyvönen M; Spring DR
Bioorg Med Chem; 2017 Jul; 25(13):3471-3482. PubMed ID: 28495381
[TBL] [Abstract][Full Text] [Related]
60. Inspecting the structure-activity relationship of protein kinase CK2 inhibitors derived from tetrabromo-benzimidazole.
Battistutta R; Mazzorana M; Sarno S; Kazimierczuk Z; Zanotti G; Pinna LA
Chem Biol; 2005 Nov; 12(11):1211-9. PubMed ID: 16298300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
